COMPANY PROFILE / #2192
Grove Biopharma
Chicago, ILVenture Capital-Backed
OVERVIEW
Operator of a modality biotechnology company intended to treat unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. The company uses artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics and also offers materials science services to peptide therapeutic challenges, enabling medical professionals with the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets.
已融资44.00
最新估值64.00
员工数9
成立年份2020
公司概况
- Companies
- Grove Biopharma
- Description
- Operator of a modality biotechnology company intended to treat unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. The company uses artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics and also offers materials science services to peptide therapeutic challenges, enabling medical professionals with the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets.
- Website
- www.grovebiopharma.com
- HQ Location
- Chicago, IL
- Year Founded
- 2020
- Keywords
- biotechnology research, inflammatory drug, intracellular protein, molecular simulation, neurodegenerative drugs, oncology biopharmaceutical, synthetic biological industry, synthetic drugs
- Competitors
- —
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 44.00
- First Financing Date
- 01-Jan-2020
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 23-Apr-2025
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 36.00
- Last Financing Valuation
- 64.00
- Last Financing Status
- Completed
- Last Known Valuation
- 64.00
- Last Known Valuation Date
- 23-Apr-2025
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 124.23
- Valuation Estimate Growth Rate
- 94.11%
- Active Investors
- DCVC Bio, Deepwork Capital, Gradiant, InVivium Capital, Joseph Mansueto, Lilly USA, Mansueto Investments, Mansueto Office, Northwestern University, Portal Innovations, Qral Ventures, Skydeck Capital, Walder Ventures
- # Active Investors
- 13
- Acquirers
- —
团队与联系人
- Employees
- 9
- Employee Growth %
- 12.50%
- Employee History
- 2025: 9, 2024: 8, 2023: 8, 2022: 5
- Primary Contact
- Laura Robinson
- Primary Contact Title
- Chief Operating Officer
- Primary Contact Email
- laura.robinson@grovebiopharma.com
- Primary Contact Phone
- —
增长与经营
- Revenue
- —
- Revenue Growth %
- —
- Growth Rate
- 0.00%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 13
- Size Multiple
- 1.81x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 68
- Majestic Referring Domains
- 47
- SimilarWeb Unique Visitors
- 436
- SimilarWeb Unique Visitors Change
- 36
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 5%
- Success Probability Over Time – 3 Year
- 16%
- Success Probability Over Time – 5 Year
- 29%
记录来源：public.companies · 原始序号 #2192 · 所有字段均按数据库原值展示。